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Introduction: Asthma with adult onset and elevated blood eosinophils is a difﬁcult-to-treat subgroup.
This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with
late-onset eosinophilic asthma.
Methods: Data from two 52-week placebo-controlled trials of reslizumab IV 3 mg/kg every 4 weeks in
patients aged 12e75 years with inadequately controlled asthma, 1 asthma exacerbation within 12
months, and screening blood eosinophils 400/mL (NCT01287039/NCT01285323) were stratiﬁed by age
of asthma onset (<40 or 40 years). Annual clinical asthma exacerbation rates, change in lung function,
and patient-reported outcomes were analyzed.
Results: 273 patients with late-onset asthma (placebo, n ¼ 130; reslizumab, n ¼ 143) and 658 with early-
onset asthma (placebo, n ¼ 336; reslizumab, n ¼ 322) were included. Baseline demographics were
similar between groups. The interaction between age at onset of asthma and effect of reslizumab on
asthma exacerbations was statistically signiﬁcant (p ¼ 0.0083). Compared with placebo, reslizumab
produced a 75% relative reduction in asthma exacerbations in patients with late-onset asthma (rate ratio
[RR] 0.25; 95% conﬁdence interval [CI], 0.16, 0.40), substantially larger than the reduction in earlier onset
patients (RR 0.58; 95% CI, 0.44, 0.76). Similar ﬁndings were observed for other measures of asthma,
including forced expiratory volume in 1 s (FEV1). The adverse event proﬁle of reslizumab was similar in
patients with early- or late-onset asthma.
Conclusions: Compared with placebo, reslizumab produced larger reductions in asthma exacerbations
and larger improvements in lung function in patients with late versus early-onset asthma.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Asthma is a heterogeneous syndrome encompassing multiple
phenotypes according to severity of symptoms, degree of airﬂow
limitation, level of asthma control, frequency of exacerbations,
nature of the underlying airway inﬂammation (eosinophilic or non-e; AE, adverse event; AQLQ,
Symptom Utility Index; BMI,
; CI, conﬁdence interval; ER,
s; ICS, inhaled corticosteroid;
acting beta agonist; LO, late
BO, placebo; Q4W, every 4
eviation.
l, De Pintelaan 185, B-9000,
elle).
r Ltd. This is an open access articleeosinophilic), and the age at onset of asthma [1]. Asthma devel-
oping for the ﬁrst time in adulthood (late onset [LO]) represents a
particularly difﬁcult-to-treat subgroup of the severe asthma pop-
ulation, and is associated with a distinctive biology and phenotypic
characteristics compared with asthma that develops in childhood
[early onset]) [1e3]. The phase 3 reslizumab population represents
mostly adult patients with uncontrolled asthma and an eosino-
philic phenotype, and encompasses patients with early-onset
asthma as well as with LO asthma [4].
Reslizumab is a high-afﬁnity, humanized anti-interleukin (IL)-5
monoclonal (IgG4/k) antibody, which inhibits activity within the IL-
5 signaling pathway by reducing ligand-receptor interactions and
reduces blood and tissue eosinophils in patients with asthma [5e7].
Add-on therapy with reslizumab (intravenous; IV) 3 mg/kg every 4
weeks (Q4W) was shown to produce signiﬁcant reductions in the
frequency of asthma exacerbations in two, replicate 52-week phaseunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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asthma patients (12 years) with elevated blood eosinophils. In
addition, treatment with reslizumab improved pulmonary func-
tion, patient-reported asthma control, symptoms and quality of life
measures [4].
The current study aims to determine the efﬁcacy of reslizumab
treatment in patients with LO asthma by secondary analysis of
pooled data from the two replicate 52-week exacerbation studies.
An age cut-off of 40 years was primarily utilized based on pre-
vious studies, which suggest that this is a reasonable age boundary
for deﬁning LO disease in asthma [8,9]; other age cut-offs for LO
asthma were also explored. Finally, the safety of reslizumab was
evaluated according to the age at onset of asthma, in order to
determine the beneﬁt:risk ratio.2. Methods
2.1. Study design and participants
Data for the analyses presented here originated from two
replicate, randomized (1:1 ratio), placebo-controlled, double-blind,
parallel-group phase 3 studies (studies 3082 [NCT01287039] and
3083 [NCT01285323]). Detailed methodology and results from the
3082 and 3083 trials have been previously reported [4]. In brief,
patients received either reslizumab (3 mg/kg) or placebo admin-
istered IV Q4W for 52 weeks. At baseline, patients (12e75 years of
age) were required to be diagnosed with asthma that was inade-
quately controlled on at least medium dose inhaled corticosteroid
(ICS)-based therapy. All patients had increased blood eosinophil
levels (400 cells/mL) at screening. Use of maintenance oral corti-
costeroids (OCS; 10 mg/kg/day of prednisone, or equivalent) was
permitted.
The studies were conducted in accordance with Good ClinicalTable 1
Patient demographics and baseline disease characteristics by age of asthma
Age of
(n ¼ 6
Age, years, mean (SD) 42 (13
Male, % 36
BMI, kg/m2, mean (SD) 27.3 (
ICSa plus LABA, n (%) 545 (8
Geographical location, n (%)
USA 86 (13
Europe 280 (4
Asia 103 (1
Other 189 (2
OCS, n (%) 98 (15
FEV1 (L), mean (SD) 2.06 (
FEV1% predicted, mean (SD) 66.5 (
ACQ6 score, mean (SD) 2.50 (
AQLQ score, mean (SD) 4.27 (
ASUI score, mean (SD) 0.65 (
Blood eosinophils, cells/mL
Mean, SD 667 (6
Median 500
Allergic disease by historyb, n (%) 438 (6
Atopy (speciﬁc IgE)c, n (%) 231 (6
Chronic sinusitis þ nasal polypsd, n (%) 89 (14
Number of exacerbations in previous 12 months
mean (SD) 1.97 (
Values are for all randomized patients (placebo þ reslizumab).
a Medium or high-dose ICS.
b Patient history of atopic dermatitis, or allergic rhinitis, or allergy shots.
c Presence of at least one ImmunoCAP test positive (0.35), study 3082
d Based on patient history. SD¼ standard deviation; BMI¼ bodymass ind
acting beta agonist; OCS ¼ oral systemic corticosteroids; FEV1 ¼ forced expi
Control Questionnaire; AQLQ ¼ Asthma Quality of Life Questionnaire; ASUIPractice guidelines, the Declaration of Helsinki, and local regulatory
requirements. Relevant health authorities and local ethics com-
mittees or institutional review boards approved the study protocols
(e-Table 1); all patients provided written informed consent.2.2. Outcomes
The frequency of clinical asthma exacerbations (CAEs) over 52
weeks for reslizumab relative to placebo is represented by a rate
ratio (RR). A CAEwas deﬁned byworsening lung function or asthma
symptoms that required a medical intervention beyond usual care
involving any of the following: systemic corticosteroid burst (3
days); increase in baseline ICS dose (doubling or more); an un-
scheduled visit to a doctor's ofﬁce for urgent asthma treatment; an
emergency room (ER) visit or a hospitalization for asthma [4]. Ex-
acerbations requiring OCS or an ER visit/hospitalization were
analyzed separately. Changes in the asthma impairment measures
of forced expiratory volume in 1 s (FEV1), Asthma Quality of Life
Questionnaire (AQLQ), Asthma Control Questionnaire (ACQ)-6 and
Asthma Symptom Utility Index (ASUI) over 52 weeks are also
reported.
This is a post hoc analysis of pooled data from replicate 52-week
asthma exacerbation studies (the 3082 and 3083 trials) by age of
asthma onset 40 years (LO asthma); additional age of onset
thresholds were also explored (age 18, 25, 30, and 35). Age of
asthma onset (years) was determined from the patient's screening
medical history information. The safety proﬁles for the patient
populations from the 3082 and 3083 trials have already been re-
ported by Castro and colleagues [4].2.3. Statistical analyses
The ratio of CAE rate between the treatment groups and its 95%onset.
onset <40 years
58)
Age of onset 40 years
(n ¼ 273)
) 58 (7)
41
5.9) 27.9 (5.3)
3) 221 (81)
) 18 (7)
3) 167 (61)
6) 52 (19)
9) 36 (13)
) 44 (16)
0.79) 1.84 (0.64)
2.1) 67.8 (18.7)
0.93) 2.46 (0.87)
1.10) 4.20 (1.02)
0.20) 0.62 (0.19)
93) 637 (467)
500
7) 134 (49)
9) 54 (41)
) 60 (22)
1.82) 1.99 (1.99)
only.
ex; ICS¼ inhaled corticosteroid; IgE¼ immunoglobulin E; LABA¼ long-
ratory volume in 1 s; PBO ¼ placebo; RES ¼ reslizumab; ACQ ¼ Asthma
¼ Asthma Symptom Utility Index.
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model. The primary negative binomial model included the treat-
ment group and randomization stratiﬁcation factors (baseline us-
age of oral corticosteroid [yes or no] and geographical region [US or
other]) as model factors and the logarithm of follow-up time
excluding the summed duration of exacerbations in the treatment
period as an offset variable. A 95% CI for the RR that excludes the
value of 1 supports the claim that the RR is different than 1, namely,
that reslizumab decreases the rate of exacerbations. Analysis of the
overall change from baseline in the impairment measures of FEV1,
AQLQ, ACQ6, and ASUI over the 52-week treatment period was
performed using a mixed-effect model for repeated measures
including treatment, visit, treatment by visit interaction, region,
OCS use at enrolment as ﬁxed factors, and covariates for baseline
value and patient as a random effect. Height and sex were also
included as ﬁxed effects for FEV1.3. Results
3.1. Patient disposition and baseline characteristics
Pooled data from 931 randomized patients from studies 3082
and 3083 were included in the post hoc analysis; 273 patients had
LO asthma (placebo, n ¼ 130; reslizumab, n ¼ 143); whereas 658
patients had asthma with an onset <40 years of age (placebo,
n ¼ 336; reslizumab, n ¼ 322).
Baseline demographics and disease characteristics are pre-
sented in Table 1. Baseline demographics and asthma control
characteristics, including lung function, asthma exacerbation his-
tory, patient-reported asthma control, and quality of life scores
were similar between the two groups. Baseline blood eosinophil
levels were also similar between patients with LO asthma and pa-
tients with age of onset <40 years. Patients with LO asthma had a
lower frequency of allergic disease and atopy compared with those
with an age of onset <40 years. In contrast, a higher proportion of
patients in the LO asthma group had chronic sinusitis with nasal
polyps.Fig. 1. Clinical asthma exacerbation (CAE) rate over 52 weeks (A), CAEs requiring
systemic corticosteroids (B), and CAEs requiring hospitalization/ER visits (C) over 52
weeks by age of asthma onset. Values in brackets represent 95% CIs. The sample
numbers for each subgroup are as follows: the total number of patients (A), the
number of patients with at least one CAE requiring corticosteroids (B), and the number
of patients with at least one CAE resulting in hospitalization/ER visits (C).
ER ¼ emergency room; RR ¼ rate ratio; IV ¼ intravenous; Q4W ¼ every 4 weeks;
CI ¼ conﬁdence interval.3.2. Efﬁcacy outcomes: asthma exacerbations
Patients in the placebo arm with LO asthma had a higher
background CAE rate compared with the overall population or
patients with age of asthma onset <40 years of age: 2.26 versus 1.81
or 1.69 CAEs per patient per year, respectively. Based on an age cut-
off of 40 years, patients with LO asthma experienced a relative
reduction in asthma exacerbations of 75% with reslizumab that was
larger than for the overall population and for patients with age of
onset <40 years (Fig. 1A; p value for interaction between age group
and treatment effect ¼ 0.0083). A similar association was observed
for exacerbations requiring OCS treatment (Fig. 1B). ER visits and
hospitalizations due to asthma were relatively uncommon in these
phase 3 clinical trials; however, exacerbations requiring an ER visit
or hospitalization were reduced by 75% in the LO subgroup versus
34% for the overall population and 12% for asthmatics with age of
onset <40 years (Fig. 1C).
The larger magnitude of reslizumab beneﬁt in reducing CAEs in
patients with LO asthma compared with the overall population and
patients with early-onset asthma was consistently observed across
a range of LO asthma age cut-offs (age of onset18, 25, 30, 35 or 40
years; Fig. 2). Across this range of age cut-offs, reslizumab treat-
ment reduced the rate of CAEs in patients with LO asthma by
68e75%.3.3. Secondary efﬁcacy outcomes
The magnitude of the improvement in FEV1 from baseline over
52 weeks with reslizumabwas similar across the overall population
and in the subgroups of patients with an age at onset <40 years and
those with LO asthma (224, 202, and 209 mL, respectively). How-
ever, the treatment difference for these groups versus placebo was
largest for the LO asthma patients (110 mL, 88 mL, and 167 mL,
respectively) due to the relatively smaller placebo effect observed
in the LO subgroup compared with the early-onset asthma
Fig. 2. Clinical asthma exacerbation (CAE) rates by age of asthma onset. RR ¼ rate ratio.
Fig. 3. Change in FEV1 over 52 weeks by age of asthma onset. Values in brackets
represent 95% CIs. FEV1 ¼ forced expiratory volume in 1 s; IV ¼ intravenous;
Q4W ¼ every 4 weeks; CI ¼ conﬁdence interval.
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the patient-reported outcomes of ACQ6 and ASUI were largest for
LO asthmatics, whereas quality of life improvements were similar
across the overall and LO subgroups (Table 2). The proportion of
ACQ6 and AQLQ responders (ie, treatment difference from placebo
0.5 units) showed only slight differences between the overall
population and LO asthma (79% versus 85% for ACQ6, and 73% versus
78% for AQLQ, respectively).
3.4. Safety
The most common adverse events (AEs) occurring among pa-
tients with LO asthma and thosewith an age of onset of asthma<40
years are shown in Table 3. Percentages of patients with at least one
AE were similar in the two groups, and slightly higher with placebo
than with reslizumab. Accordingly, most AEs (both system organ
classes and preferred terms) affected similar percentages of pa-
tients with versus without LO asthma.
4. Discussion
Patients with LO asthma appear to represent a clinically
distinctive and often severe form of the disease [10]. The deﬁning
age for LO of asthma varies in the literature, with early onset
typically used to describe symptoms developing during childhood
and LO asthma deﬁned as asthmawith onset in adulthood (broadly
deﬁned as after age 18 years or 40 years) [11,12]. The aim of this post
hoc analysis of the pooled data from two replicate, phase 3 studies
of reslizumab (3 mg/kg IV Q4W) in uncontrolled eosinophilic
asthma was to assess the comparative efﬁcacy of reslizumab in
patients with LO asthma versus early-onset asthma.
Patients with inadequately controlled LO asthma, deﬁned by age
of onset 40 years, were more prone to asthma exacerbations than
the overall population or patients with age of onset <40 years,
based on higher exacerbation rates during placebo treatment; this
result supports the observation that asthma is more severe in this
subpopulation. Of note, placebo-treated patients with LO asthma
also had a lower FEV1 response to standard of care treatment
compared with the overall population and patients with age ofonset <40 years, which is also consistent with more severe disease
(Fig. 3). LO asthma patients had a marked response to reslizumab
(75% reduction in both CAEs and in events requiring a hospitali-
zation or ER visit) that was larger than that observed for the overall
study population or patients with age of onset <40 years (54% and
34% reduction, respectively). Treatment differences between resli-
zumab and placebo in measures of current asthma impairment
were also numerically larger for LO patients compared with the
overall population: lung function (FEV1: 167 mL versus 110 mL),
patient-reported asthma control (ACQ6:0.363 versus0.238) and
patient-reported asthma symptoms (ASUI: 0.061 versus 0.049).
Different deﬁnitions of LO asthma, ranging from age of onset of18
years to 40 years of age, were tested and produced similarly large
reductions in the rate of exacerbations with reslizumab relative to
placebo. The safety proﬁle of reslizumab was similar in LO asthma
patients and those with an age of onset <40 years.
It is possible that differences in the pathobiology between the
overall eosinophilic asthma population and those with LO asthma
may contribute to the apparent differences in the magnitude of
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vations, patients in this study with LO asthma were more likely to
have chronic sinusitis and nasal polyps, less atopy, and fewer co-
morbid allergic diseases compared with patients without LO
asthma (Table 1) [2,10,13]. Indeed, a separate post hoc analysis using
data from the same overall populations as the current analysis
found that patients with nasal polyps and chronic sinusitis
beneﬁted most from reslizumab (versus the overall population) e
this included an 83% reduction in the annual rate of CAEs relative to
placebo (p ¼ 0.0002) [14]. This provides further support for the use
of reslizumab in patients with LO eosinophilic asthma.
Early-onset asthma may be described as being primarily driven
by atopy and typiﬁed by type 2 cytokine expression (including IL-5)
with consequential eosinophilia [15]. In contrast, in LO asthmaTable 3
Adverse events by age of asthma onset.
Age of onset <40 ye
Placebo
(n ¼ 336)
At least one AE 285 (85)
Cardiac disorders 22 (7)
Gastrointestinal disorders 48 (14)
General disorders and administration site conditions 37 (11)
Fatigue 7 (2)
Infections and infestations 201 (60)
Nasopharyngitis 66 (20)
Upper respiratory tract infection 31 (9)
Respiratory tract infection 6 (2)
Sinusitis 26 (8)
Urinary tract infection 15 (4)
Inﬂuenza 24 (7)
Pharyngitis 14 (4)
Bronchitis 29 (9)
Rhinitis 16 (5)
Injury, poisoning and procedural complications 33 (10)
Clinical laboratory results 33 (10)
Blood creatinine phosphokinase increased 7 (2)
Metabolism and nutrition disorders 18 (5)
Musculoskeletal and connective tissue disorders 48 (14)
Back pain 14 (4)
Nervous system disorders 58 (17)
Headache 34 (10)
Respiratory, thoracic and mediastinal disorders 199 (59)
Asthma 172 (51)
Dyspnea 10 (3)
Cough 12 (4)
Skin and subcutaneous tissue disorders 33 (10)
Vascular disorders 9 (3)
AE¼ adverse event. System organ classes and preferred terms reported in5% of patients
shown are numbers of patients (%).
Table 2
Change from baseline in AQLQ, ACQ6 and ASUI over 52 weeks by age of asthma onset.
Overall
Placebo
(n ¼ 476)
Reslizumab
(n ¼ 477)
ACQ6
n
LS mean change from baseline 0.85 1.087
Treatment difference (95% CI) 0.238 (0.336, 0.140)
AQLQ
n
LS mean change from baseline 0.813 1.084
Treatment difference (95% CI) 0.272 (0.155, 0.388)
ASUI
n
LS mean change from baseline 0.122 0.171
Treatment difference (95% CI) 0.049 (0.033, 0.065)
AQLQ ¼ Asthma Quality of Life Questionnaire; ACQ ¼ Asthma Control Questionnaire; AS(formerly called intrinsic asthma), the exogenous causes of the
disease are largely unknown, although environmental stimuli such
as oxidants (for example, chronic cigarette smoke exposure) or
microbes might be involved. These agents may cause airway
epithelial cells to secrete cytokines that activate innate lymphoid
type 2 (ILC2) cells to produce IL-5 in an allergen-independent
manner [2,16]. Moreover, increased numbers of IL-5-producing
ILC2 cells have been observed in the airways of patients with se-
vere LO asthma [17], as well as in patients with chronic rhinosi-
nusitis and nasal polyps [16], despite treatment with high-dose ICS
and even OCS, suggesting that ILC2 cells are relatively corticoste-
roid resistant. We put forward the hypothesis that the
corticosteroid-resistant production of IL-5 by ILC2 cells underlies
the persistent eosinophilic airway inﬂammation in LO asthmatics,ars Age of onset 40 years
Reslizumab
(n ¼ 322)
Placebo
(n ¼ 130)
Reslizumab
(n ¼ 143)
255 (79) 114 (88) 110 (77)
13 (4) 11 (8) 3 (2)
45 (14) 23 (18) 22 (15)
30 (9) 22 (17) 12 (8)
4 (1) 7 (5) 1 (<1)
173 (54) 81 (62) 69 (48)
49 (15) 23 (18) 24 (17)
30 (9) 15 (12) 15 (10)
8 (2) 7 (5) 7 (5)
24 (7) 13 (10) 6 (4)
14 (4) 6 (5) 5 (3)
16 (5) 6 (5) 4 (3)
12 (4) 7 (5) 4 (3)
13 (4) 6 (5) 2 (1)
9 (3) 3 (2) 6 (4)
22 (7) 10 (8) 13 (9)
29 (9) 9 (7) 16 (11)
6 (2) 4 (3) 8 (6)
18 (6) 8 (6) 9 (6)
44 (14) 18 (14) 21 (15)
19 (6) 6 (5) 5 (3)
49 (15) 21 (16) 26 (18)
35 (11) 12 (9) 16 (11)
152 (47) 79 (61) 59 (41)
123 (38) 67 (52) 37 (26)
6 (2) 7 (5) 6 (4)
12 (4) 8 (6) 2 (1)
32 (10) 14 (11) 17 (12)
12 (4) 4 (3) 7 (5)
receiving either placebo or reslizumab (in either age of onset group) are shown. Data
Age of onset <40 years Age of onset 40 years
Placebo
(n ¼ 336)
Reslizumab
(n ¼ 322)
Placebo
(n ¼ 130)
Reslizumab
(n ¼ 143)
330 320 129 140
0.805 0.996 0.977 1.34
0.191 (0.309, 0.074) 0.363 (0.549, 0.177)
317 301 125 136
0.735 1.041 0.925 1.19
0.306 (0.166, 0.447) 0.265 (0.046, 0.484)
323 315 129 138
0.104 0.149 0.165 0.226
0.046 (0.027, 0.064) 0.061 (0.031, 0.091)
UI ¼ Asthma Symptom Utility Index; LS ¼ least-squares; CI ¼ conﬁdence interval.
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Although the magnitude of tissue inﬂammation and blood eosin-
ophilia can be similar in early and LO asthma (Table 1), IL-5
signaling is likely to underlie the greater proportion of symptom-
related ICS-resistant signaling in LO asthma.
Themain limitation of the study is that this post hoc analysis was
not predeﬁned and prospective controlled studies are needed to
conﬁrm these observations. However, the post hoc analysis was
based upon a strong scientiﬁc rationale (ie, the presence of different
endotypes of eosinophilic asthma according to the age at onset) [2].
Also, these observations are likely not applicable to patients with
LO asthma who do not have an eosinophilic phenotype, as this was
a requirement for inclusion. The parameter of age of asthma onset
was necessarily patient reported and may therefore be imprecise.
However, this approach clearly seems to identify a reslizumab-
responsive LO asthma subgroup from the overall population and
is consistent with the collection of a standard asthma history as
would be used by healthcare professionals in everyday clinical
practice. Finally, as this was a primarily adult population (age of
inclusion for the phase 3 reslizumab trials was12 years; however,
only 25 patients age 12 to17 years were randomized in the pooled
dataset), the effect of reslizumab in adolescent patients with early-
onset asthma remains to be elucidated.
In conclusion, patients with exacerbation-prone, LO asthma
with elevated blood eosinophil levels (400 cells/mL) and inade-
quately controlled symptoms responded particularly well to resli-
zumab, relative to the overall study population. These results
contribute to our understanding of the heterogeneity of eosino-
philic asthma and help to identify those patients most likely to
achieve a clinically meaningful response to reslizumab.
Trial registry
ClinicalTrials.gov; NCT01287039 and NCT01285323.
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